Berberine promotes the degradation of phenylacetic acid to prevent thrombosis by modulating gut microbiota
Authors:
- 7 March 2024
- journal article
- research article
- Published by Elsevier in Phytomedicine
- Vol. 128, 155517
Abstract
No abstract availableKeywords
Funding Information
- National Natural Science Foundation of China
This publication has 24 references indexed in Scilit:
- Clinical Evaluation and Management of Thrombotic MicroangiopathyArthritis & Rheumatology, 2023
- Unravelling Surface Modification Strategies for Preventing Medical Device‐Induced ThrombosisAdvanced Healthcare Materials, 2023
- Trimethylamine N-Oxide and White Matter Hyperintensity Volume Among Patients With Acute Ischemic StrokeJAMA Network Open, 2023
- Map of thrombogenesis in viral infections and viral-driven tumoursDiscover Oncology, 2023
- Berberine ameliorates chronic kidney disease through inhibiting the production of gut-derived uremic toxins in the gut microbiotaActa Pharmaceutica Sinica B, 2022
- Gut microbiota specifically mediates the anti-hypercholesterolemic effect of berberine (BBR) and facilitates to predict BBR’s cholesterol-decreasing efficacy in patientsJournal of Advanced Research, 2021
- A Cardiovascular Disease-Linked Gut Microbial Metabolite Acts via Adrenergic ReceptorsCell, 2020
- Implication of gut microbiota metabolites in cardiovascular and metabolic diseasesCellular and Molecular Life Sciences, 2018
- Epidemiology of venous thromboembolism in the Framingham Heart StudyThrombosis Research, 2016
- Role of oxidative stress on platelet hyperreactivity during agingLife Sciences, 2016